BlackRock Amends Pacira BioSciences Stake (12th Amendment)
Ticker: PCRX · Form: SC 13G/A · Filed: Jan 19, 2024 · CIK: 1396814
| Field | Detail |
|---|---|
| Company | Pacira Biosciences, Inc. (PCRX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**BlackRock updated its Pacira BioSciences holdings as of year-end 2023.**
AI Summary
BlackRock Inc. has filed an amended Schedule 13G/A for Pacira BioSciences, Inc. (NASDAQ: PCRX), indicating a change in their beneficial ownership as of December 31, 2023. This amendment, number 12, updates their previous holdings in Pacira's Common Stock. This matters to investors because BlackRock is a major institutional investor, and changes in their stake can signal shifts in their confidence or investment strategy regarding Pacira BioSciences, a pharmaceutical company.
Why It Matters
Changes in major institutional ownership can influence stock price and investor sentiment, as large funds often conduct extensive due diligence.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not inherently signal high risk.
Analyst Insight
Investors should monitor future 13G/A filings from BlackRock to track any significant changes in their ownership percentage, which could indicate a shift in their long-term view of Pacira BioSciences.
Key Players & Entities
- BlackRock Inc. (company) — filer of the SC 13G/A, a major institutional investor
- Pacira BioSciences, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring this filing
Forward-Looking Statements
- BlackRock will continue to be a significant institutional holder of Pacira BioSciences stock. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 12, as stated in the filing.
Who is the subject company of this filing?
The subject company is Pacira BioSciences, Inc., as clearly stated under 'Name of Issuer' in the filing.
Who filed this Schedule 13G/A?
This Schedule 13G/A was filed by BlackRock Inc., as indicated in the 'FILED BY' section of the filing.
What is the CUSIP number for the securities reported?
The CUSIP number for the Common Stock of Pacira BioSciences, Inc. is 695127100, as listed in the filing.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified in the document.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 19, 2024 regarding Pacira BioSciences, Inc. (PCRX).